68-5

82/120

532Komuro I, Komori K, Takahashi K, Tanemoto K, Hasegawa H, Harigai M, Fujimoto S, Miyazaki T, Miyata T, Yamada H, Yoshida A, Wada T, Inoue Y, Uchida HA, Ota H, Okazaki T, Onimaru M, Kawakami T, Kinouchi R, Kurata A, Kosuge H, Sada KE, Shigematsu K, Suematsu E, Sueyoshi E, Sugihara T, Sugi‑yama H, Takeno M, Tamura N, Tsutsumino M, Dobashi H, Nakaoka Y, Nagasaka K, Maejima Y, Yoshifuji H, Watanabe Y, Ozaki S, Kimura T, Shigematsu H, Yamauchi-Taki‑hara K, Murohara T, Momomura SI: JCS Joint Working Group. JCS 2017 Guideline on Management of Vasculitis Syndrome- Digest Version. Circ J, 2020; 84: 299-359.＊ 2) Nakaoka Y, Isobe M, Tanaka Y, Ishii T, Ooka S, Niiro H, Tamura N, Banno S, Yoshifuji H, Sakata Y, Kawakami A, Atsumi T, Furuta S, Kohsaka H, Suzuki K, Hara R, Maejima Y, Tsukamoto H, Takasaki Y, Yamashita K, Okada N, Yamakido S, Takei S, Yokota S, Nishimoto N: Long-term efficacy and safety of tocilizumab in refractory Takayasu arte‑ritis: final results of the randomized controlled phase 3 TAKT study, Rheumatology, 2020; 59: 2427-2434.＊ 3) Abe Y, Kusaoi M, Tada K, Yamaji K, Tamura N: Successful treatment of anti-MDA5 anti‑body-positive refractory interstitial lung disease with plasma exchange therapy. Rheu‑matology (Oxford), 2020; 59: 767-771.＊ 4) Murayama G, Chiba A, Kuga T, Makiyama A, Yamaji K, Tamura N, Miyake S: Inhibition of mTOR suppresses IFNα production and the STING pathway in monocytes from systemic lupus erythematosus patients. Rheu‑matology (Oxford), 2020; 59: 2992-3002.＊ 5) Matsuoka Y, Morimoto S, Fujishiro M, Haya‑kawa K, Kataoka Y, Suzuki S, Ikeda K, Taka‑mori K, Yamaji K, Tamura N: Metformin repositioning in rheumatoid arthritis. Clin Exp Rheumatol, 2020; Online ahead of print.＊ 6) Kogami M, Suzuki S, Nanjo Y, Ikeda K, Tamura N, Sasaki S, Morimoto S: Complica‑tion of coronavirus disease 2019 during remis‑sion induction therapy against anti-MDA5 antibody-positive dermatomyositis. Rheumatol Adv Pract, 2020; 4: rkaa068.＊ 7) Abe Y, Fujibayashi K, Nishizaki Y, Yanagi‑sawa N, Nojiri S, Kon T, Tada K, Yamaji K, Tamura N: Conventional versus Rapid Gluco‑corticoid Tapering in Severe Systemic Lupus Erythematosus Patients: A Non-Blind, Randomized Controlled Trial. Acta Med Okayama, 2020; 74: 179-183.＊ 8) Abe Y, Yamaji K, Endo Y, Kusaoi M, Nakano S, Yang KS, Tada K, Tsuda H, Tamura N： Plasma exchange therapy to reduce mortality in japanese patients with diffuse alveolar hemorrhage and microscopic polyangiitis. Ther Apher Dial, 2020; 24: 208-214.＊ 9) Kusaoi M, Murayama G, Tamura N, Yamaji K: Reimbursement for therapeutic apheresis devices and procedures for using the health‑care insurance system in Japan. Ther Apher Dial, 2020; 24: 530-547.＊ 10) Nakajima S, Chiba A, Makiyama A, Hayashi E, Murayama G, Yamaji K, Kobayashi S, Tamura N, Takasaki Y, Miyake S: Association of mucosal-associated invariant T cells with different disease phases of polymyalgia rheu‑matica. Rheumatology (Oxford), 2020; 59: 2939-2946.＊ 11) Izawa K, Kaitani A, Ando T, Maehara A, Nagamine M, Yamada H, Ando T, Ide T, Matsuzawa M, Okamoto Y, Yin E, Fukase S, Wang H, Kamei A, Uchida S, Maeda K, Nakano N, Uchida K, Tamura N, Ikeda K, Ebihara N, Shimizu T, Voehringer D, Roers A, Ogawa H, Okumura K, Kitaura J: Differen‑tial Lipid Recognition by Mouse versus Human CD300f, Inhibiting Passive Cutaneous Anaphylaxis, Depends on a Single Amino Acid Substitution in its Immunoglobulin-Like Domain． J Invest Dermatol, 2020; 140: 710-713.＊ 12) Matsuki-Muramoto Y, Ogasawara M, Kawa‑moto T, Yamaji K, Tamura N: Picture superi‑ority effect as one of the potential advantages of musculoskeletal ultrasound complementa‑tion for verbal explanation. Mod Rheumatol, 2020; 30: 748-751.＊ 13) Minowa K, Ogasawara M, Matsuki-Mura‑moto Y, Kawamoto T, Yamaji K, Tamura N: Ultrasound versus clinical joint level assess‑ment to predict structural damage in rheu‑matoid arthritis patients receiving biological therapy: a prospective study. Clin Exp Rheu‑matol, 2020; 38: 801.